^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Cell Lung Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN SCLC Panel recommends pembrolizumab as a subsequent therapy option for patients with SCLC, regardless of PD-L1 levels…
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Clin Oncol
    Title:

    Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

    Published date:
    05/29/2020
    Excerpt:
    Twelve-month PFS estimates were 13.6% with pembrolizumab plus EP and 3.1% with placebo plus EP….Pembrolizumab plus EP significantly improved PFS compared with placebo plus EP as first-line therapy for patients with ES-SCLC. Pembrolizumab plus EP significantly improved PFS compared with placebo plus EP as first-line therapy for patients with ES-SCLC.
    Secondary therapy:
    EP
    DOI:
    10.1200/JCO.20.00793
    Trial ID:
    KEYNOTE-604